Skip to content

Rezera Inc.

Boston Business Watch reported on Rezera Inc. on October 7, 2026.

What we have reported

  1. October 7, 2026

    Boston Biotech Rezera Says Its Pill Boosts Semaglutide's Anti-Inflammatory Effect

    Boston-based Rezera Inc. said on October 7, 2026 that its experimental oral drug ruvonoflast produced added reductions in an inflammation marker when given alongside the weight-loss drug semaglutide, according to a company announcement distributed by GlobeNewswire. Rezera said the combination was generally well tolerated, with no new safety signals.